Evidence map›Paper›PMID 41560841›Full record

ArticleMaterials today. Bio2026

Design and

Khalil Elbadri, Manlio Fuscielo, Firas Hamdan, Ruoyu Cheng, Sara Feola, Honey Bokharaie, Carmine D'Amico, Giuseppina Molinaro, Alexandra Correia, Shiqi Wang and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Khalil ElbadriDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Manlio FuscieloDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki, FI-00014, Finland.
Firas HamdanDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki, FI-00014, Finland.
Ruoyu ChengDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Sara FeolaOrion Corporation, Turku, Finland.
Honey BokharaieDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Carmine D'AmicoDepartment of Bioproducts and Biosystems, Aalto University, 00076, Aalto, Finland.
Giuseppina MolinaroDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Alexandra CorreiaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Shiqi WangDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, FI-00014, Finland.
Michael JeltschDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki, FI-00014, Finland.
Vincenzo CerulloDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, Helsinki, FI-00014, Finland.
Hélder A SantosDepartment of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA interference (RNAi) is a powerful tool for post-transcriptional gene silencing, yet its clinical translation remains limited by the lack of safe and efficient delivery systems. In this study, we evaluated the potential of plant virus-like particles (VLPs), derived from Brome Mosaic Virus (BMV), as a biodegradable and biocompatible nanocarrier for small interfering RNA (siRNA) delivery aimed at modulating immune checkpoints in melanoma. Recombinant BMV capsid proteins were expressed in

Indexed as

Melanoma immunotherapyPD-L1 silencingPlant virus nanocarriersProtein cagessiRNA delivery

Identifiers

PMID41560841
PMCPMC12813231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.